$3.11
+0.09 (+2.98%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where ELTX is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
2 interventional · 1 expanded access · 1 with posted results
Held by 0 tracked-famous managers · FINRA short interest 5.1 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid TumorsNCT05726864Phase 1: Evaluate the safety of ELI-002 7PRandomized · Open-label · Treatment | Phase 1/2 | Active, not recruiting | Drug: ELI-002 7P | Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, KRAS G12D, KRAS G12R, KRAS G12V, KRAS G12A, KRAS G12C, KRAS G12S, KRAS G13D, NRAS G12D, NRAS G12R, NRAS G12V, NRAS G12C, NRAS G12S | 158 | 2026-04-20actual | 2026-07-10 |
| A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid TumorsNCT04853017results2025-01-17The Participant Incidence of Treatment-emergent Adverse Events Considered by the Investigator as Related to ELI-002Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: ELI-002 2P | Minimal Residual Disease, KRAS G12D, KRAS G12R, NRAS G12D, NRAS G12R, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Non-small Cell Lung Cancer, Ovarian Cancer, Cholangiocarcinoma, Bile Duct Cancer, Gallbladder Carcinoma | 25 | 2023-01-26actual | 2025-09-05 |
| Expanded Access Protocol of ELI-002-102 in Subjects With KRAS/NRAS Mutated Pancreatic Ductal AdenocarcinomaNCT07083479expanded access | — | No longer available | Drug: ELI-002 7P | Pancreatic Ductal Adenocarcinoma, KRAS G12D, KRAS G12V, KRAS G12S, KRAS G12A, KRAS G12C, KRAS G12R, KRAS G13D, NRAS G12D, NRAS G12V, NRAS G12S, NRAS G12A, NRAS G12C, NRAS G12R, NRAS G13D | — | — | 2026-07-10 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19